Organon vs BeOne Medicines
OGN and ONC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OGN and ONC compare
BeOne Medicines is the larger company, worth 151 times as much as Organon ($547B against $3.6B).
On earnings, Organon is cheaper: it trades at 18.0× trailing earnings, against 861× for BeOne Medicines.
BeOne Medicines grew revenue faster over the last twelve months (34.3% versus −3.2% for Organon).
BeOne Medicines keeps more of each dollar of sales as profit, with a net margin of 10.7% compared with 3.5% at Organon.
Organon pays a dividend yielding 0.58%; BeOne Medicines does not pay one.
BeOne Medicines scores higher on the StockData Score (12 against 8 for Organon), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OGN | ONC |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | $547B |
| Share price | $13.84 | $370.33 |
| Change, 1 year | 118% | 17.6% |
| Change, 5 years | −61.9% | 1.5% |
| Beta (5Y) | 0.83 | 1.07 |
| Employees | 10K | 12K |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 18.0× (better) | 861× |
| P/S | 0.6× (better) | 89.3× |
| P/B | 3.0× (better) | 106× |
| EV/EBITDA | – | 504× |
| P/FCF | 5.4× (better) | 412× |
| FCF yield | 18.6% (better) | 0.24% |
| Fair value | $14.66 | $15.35 |
| Margin of safety | 5.6% (better) | −2313% |
| Growth | ||
| Revenue growth (TTM) | −3.2% | 34.3% (better) |
| Revenue growth, 5Y average | −0.99% | 76.8% (better) |
| Net income growth (TTM) | −57.5% | – |
| EPS growth (TTM) | −59.9% | – |
| EPS growth, 5Y average | −39.0% | – |
| Profitability | ||
| Gross margin | 53.1% | 88.9% (better) |
| Operating margin | – | 15.1% |
| Net margin | 3.5% | 10.7% (better) |
| FCF margin | 11.1% | 21.7% (better) |
| Return on equity | 20.3% (better) | 14.7% |
| Return on invested capital | – | 43.7% |
| Financial health | ||
| Debt / equity | 7.17 | 0.22 (better) |
| Net debt / EBITDA | – | −3.67 |
| Interest coverage | – | 8.7× |
| Current ratio | 2.02 | 3.40 (better) |
| Altman Z-score | 1.03 | 82.54 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.58% | – |
| Payout ratio | 9.4% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.58% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 83.3% | 2.4% |
| Held by insiders | 0.49% | 13.9% |
| Insider net buying, 12 months | $301K (better) | −$369M |
| Short interest, % of float | 7.3% | – |
Go deeper
- OGN stock overview
- OGN income statement
- OGN valuation and score
- ONC stock overview
- ONC income statement
- ONC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.